HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

JM 3100

a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2; partial structure given in first source

Also Known As:

1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)octahydrochloride dihydrate; 1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate; AMD 3100; AMD 3329; AMD-3100; AMD-3329; AMD3100; JM-3100; JM3100; bicyclam; mezobil; mozobil; plerixafor; plerixafor hydrochloride

Networked: 458 relevant articles (61 outcomes, 77 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- JM 3100: 458

Experts

1.	Calandra, Gary: 23 articles (12/2013 - 10/2003)
2.	Bridger, Gary: 14 articles (10/2012 - 09/2002)
3.	DiPersio, John F: 10 articles (12/2013 - 03/2004)
4.	Schols, Dominique: 9 articles (03/2015 - 04/2002)
5.	De Clercq, Erik: 8 articles (12/2010 - 07/2002)
6.	Maziarz, Richard T: 7 articles (12/2013 - 06/2009)
7.	Stiff, Patrick J: 7 articles (12/2013 - 06/2009)
8.	Badel, Karin: 7 articles (05/2010 - 03/2004)
9.	Bridger, G: 7 articles (01/2010 - 01/2000)
10.	Laufs, Stephanie: 6 articles (02/2014 - 08/2006)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2013 - "AMD3100 achieved a potent inhibition of tumor growth without significant reduction in blood vessel density. " 08/01/2012 - "Furthermore, we used AMD3100, a CXCR4 antagonist, to mobilize the leukemic cells protected in the bone marrow (BM) microenvironment and the combination with rGel/BLyS resulted in a significant reduction of the tumor load in the BM and complete eradication of ALL cells from the circulation. " 11/01/2012 - "Plerixafor may be an effective and safe agent for stem cell collection in pediatric patients with solid tumors, although new studies addressed to evaluate its effectiveness and safety are needed." 12/01/2013 - "We therefore conducted a prospective trial to determine whether a one-day mobilization by plerixafor alone was efficient enough in children with cancer. " 11/01/2011 - "(nat)Ga-CPCR4-2 exhibits high CXCR4 affinity with a half maximum inhibitory concentration of 4.99 ± 0.72 nM. (68)Ga-CPCR4-2 showed high in vivo stability and high and specific tumor accumulation, which was reduced by approximately 80% in competition studies with AMD3100. "
2.	Multiple Myeloma 02/01/2015 - "Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma." 12/01/2014 - "We retrospectively assessed the effect of an early plerixafor rescue regimen for mobilization in patients with multiple myeloma. " 11/01/2014 - "We present data on the pharmacoeconomic impact of the use of plerixafor as an up-front mobilization in patients with multiple myeloma (MM). " 08/01/2013 - "We report a series of 14 patients with multiple myeloma or NHL successfully mobilized and harvested by plerixafor together with large-volume leukaphereses (LVL). " 04/01/2011 - "Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor."
3.	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/01/2012 - "[Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma]." 09/01/2011 - "Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor." 08/01/2012 - "The aim of this study was to assess effects of plerixafor added to chemomobilization on graft CD34(+) cell subclasses, lymphocyte subsets, engraftment, and post-transplant course in non-Hodgkin lymphoma (NHL) patients. " 10/01/2015 - "Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison." 05/01/2014 - "Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients."
4.	Lymphoma (Lymphomas) 02/01/2015 - "The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined as a total yield >2×10(6) CD34+ cells/kg) of 77%, and well tolerated (one SAE reported). " 08/01/2007 - "AMD3100 was generally safe and improved PBSC and DC cell mobilization with no apparent contamination of lymphoma cells." 01/01/2016 - "We conclude that plerixafor administration is safe and efficient for upfront mobilization in lymphoma patients predicted to be poor mobilizers. " 12/01/2015 - "We evaluated 136 patients with myeloma or lymphoma who underwent mobilization with 2 approaches of plerixafor utilization. " 08/01/2014 - "An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor."
5.	Hodgkin Disease (Hodgkin's Disease) 01/01/2016 - "We initiated a study to assess the use of plerixafor as a first-line stem cell mobilizer in 20 elderly or heavily pretreated patients with non-Hodgkin or Hodgkin lymphoma. " 03/01/2013 - "Use of plerixafor in patients with Hodgkin lymphoma with poor mobilization of peripheral blood stem cells." 08/01/2014 - "Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization." 02/01/2015 - "This open-label, prospective, observational study was conducted in 11 Belgian centres in 114 patients with lymphoma (Hodgkin's and non-Hodgkin's lymphoma) or MM who were treated with plerixafor according to the SmPC between April 2011 and October 2012. " 08/01/2011 - "Successful mobilization with plerixafor and autologous hematopoietic SCT in a patient with refractory Hodgkin's lymphoma and Gaucher disease."

Related Drugs and Biologics

1.	Granulocyte Colony-Stimulating Factor (G-CSF)
2.	JM 3100
3.	Chemokine CXCL12
4.	CXCR4 Receptors (CXCR4 Receptor)
5.	Cyclophosphamide (Cytoxan)
6.	rituximab (Mabthera)
7.	docetaxel (Taxotere)
8.	Bleomycin (Blenoxane)
9.	sunitinib (Sutent)
10.	Hydroxyurea (Hydrea)

Related Therapies and Procedures

1.	Blood Component Removal (Apheresis)
2.	Hematopoietic Stem Cell Mobilization
3.	Transplantation (Transplant Recipients)
4.	Drug Therapy (Chemotherapy)
5.	Transplants (Transplant)